Quick Answer
Cogent Biosciences, Inc. reported Net Income of -$328.94 million for fiscal year 2025.
Cogent Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$328.94M -28.6% |
-$255.86M -33.0% |
-$192.41M -37.2% |
-$140.24M -94.0% |
-$72.27M +3.4% |
-$74.81M -135.0% |
| Diluted EPS | -$2.16 -11.3% |
-$1.94 +0.0% |
-$1.94 -12.1% |
-$1.73 +7.5% |
-$1.87 | — |
| Total Assets | $937.61M +185.9% |
$327.90M +4.6% |
$313.44M +4.2% |
$300.81M +29.6% |
$232.09M -7.5% |
$250.92M +407.7% |
| Cash and Equivalents | $312.01M +217.8% |
$98.17M +84.4% |
$53.23M -61.9% |
$139.89M -36.3% |
$219.68M -9.3% |
$242.19M +547.2% |
| Stockholders Equity | $636.37M +148.3% |
$256.29M -0.6% |
$257.80M +0.8% |
$255.74M +19.4% |
$214.18M -8.7% |
$234.67M +638.8% |
| R&D Expense | $269.78M +16.0% |
$232.66M +33.9% |
$173.75M +42.9% |
$121.63M +117.5% |
$55.91M +117.2% |
$25.74M -41.1% |
| Operating Income | -$333.36M -20.8% |
-$275.94M -32.6% |
-$208.13M -40.8% |
-$147.84M -95.7% |
-$75.55M +8.1% |
-$82.20M -155.5% |
| Shares Outstanding | 160.98M +45.7% |
110.46M +28.3% |
86.12M +23.2% |
69.89M +59.6% |
43.81M +35.4% |
32.35M +322.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$80.93M | -14.6% | -10.1% |
| Diluted EPS | September 30, 2025 | -$0.50 | +3.8% | +5.7% |
| Total Assets | September 30, 2025 | $425.93M | +10.9% | +55.0% |
| Cash and Equivalents | September 30, 2025 | $125.30M | +29.1% | -1.8% |
| Long-Term Debt | September 30, 2025 | $44.25M | — | +0.7% |
| Stockholders Equity | September 30, 2025 | $302.46M | -3.9% | +95.1% |
| R&D Expense | September 30, 2025 | $68.99M | +8.4% | +10.9% |
| Operating Income | September 30, 2025 | -$83.36M | -10.5% | -10.3% |
| Shares Outstanding | September 30, 2025 | 139.83M | +26.6% | +22.7% |
- Cogent Biosciences, Inc. reported Net Income of -$328.94 million for fiscal year 2025.
- Cogent Biosciences, Inc. showed a decrease of -28.6% in Net Income compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported Diluted EPS of $2.16 per share (loss) for fiscal year 2025.
- Cogent Biosciences, Inc. showed a decrease of -11.3% in Diluted EPS compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported Total Assets of $937.61 million for fiscal year 2025.
- Cogent Biosciences, Inc. showed an increase of +185.9% in Total Assets compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported Cash and Equivalents of $312.01 million for fiscal year 2025.
- Cogent Biosciences, Inc. showed an increase of +217.8% in Cash and Equivalents compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported Stockholders Equity of $636.37 million for fiscal year 2025.
- Cogent Biosciences, Inc. showed an increase of +148.3% in Stockholders Equity compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported R&D Expense of $269.78 million for fiscal year 2025.
- Cogent Biosciences, Inc. showed an increase of +16.0% in R&D Expense compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported Operating Income of -$333.36 million for fiscal year 2025.
- Cogent Biosciences, Inc. showed a decrease of -20.8% in Operating Income compared to the prior fiscal year.
- Cogent Biosciences, Inc. reported Shares Outstanding of 160.98 million shares for fiscal year 2025.
- Cogent Biosciences, Inc. showed an increase of +45.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: